Abstract
Oscar Health, Inc. is scheduled to report third-quarter results on November 5, 2026, Pre-MKt; investors will watch whether revenue tracks to the roughly 4.72 billion US dollars model and if margin and EPS trends sustain recent improvements.Market Forecast
Consensus models point to revenue of about 4.72 billion US dollars for the quarter to be reported, up 53.24% year over year, with EPS around -0.22, an improvement of 61.41% year over year, and EBIT near -62.58 million US dollars, up 47.13% year over year on a comparative basis; formal gross margin and net margin guidance for the quarter have not been provided. The main business remains premium revenue before ceded reinsurance, and management commentary will likely focus on membership quality, churn dynamics, and pricing discipline into year-end. The most promising earnings driver continues to be the “premiums before ceded reinsurance” line, which totaled 4.79 billion US dollars last quarter and represented 98.14% of revenue; given that overall revenue grew 70.40% year over year, this line item effectively dominated topline expansion and remains the key lever for this quarter’s trajectory.Last Quarter Review
The previous quarter delivered revenue of 4.88 billion US dollars, up 70.40% year over year, a gross profit margin of 22.25%, GAAP net profit attributable to the parent of 362.00 million US dollars, a net profit margin of 7.41%, and adjusted EPS of 1.10, up 223.60% year over year. On a sequential basis, net profit decreased 46.71%, underscoring that quarter-to-quarter dynamics can be volatile even amidst strong year-over-year gains. By business line, premiums before ceded reinsurance were 4.79 billion US dollars, investment income was 84.79 million US dollars, and services and other were 6.10 million US dollars; the outsized contribution of premiums meant topline growth tracked the core insurance activity.Current Quarter Outlook
Main business: premium revenue and medical-cost performance
All eyes are on the premium revenue engine and its intersection with medical-cost utilization and pricing precision. Commentary from management and peer updates have pointed to better-than-expected utilization trends this year, and sell-side previews suggest that recent guidance already embedded some of this improvement. The message for the quarter is less about a new inflection and more about execution against that embedded improvement—keeping medical loss dynamics contained, while maintaining selective growth and protecting the pricing mix. On the revenue side, the model figure of roughly 4.72 billion US dollars implies that the core premium book continues to expand at a brisk year-over-year rate, with membership quality, risk adjustment, and pricing as the principal moving parts. The prior-quarter gross margin of 22.25% and net margin of 7.41% serve as a baseline for how investors will judge progress this quarter; a stable to modestly improved spread between the premium yield and underlying medical costs would help validate the EPS improvement path implied by models. Because premiums before ceded reinsurance represent the overwhelming majority of revenue, any deviation in medical-cost trends versus expectations—whether from mix, claim development, or short-term utilization blips—can have outsized effects on margin optics. Management’s discussion around reinsurance cessions, reserve development, and risk-adjustment outcomes will thus be critical for interpreting whether the improvement in EPS (modeled at -0.22, up 61.41% year over year) is building a foundation for subsequent quarters or reflects timing-related benefits that might normalize.Most promising business driver: ACA-focused individual and small-group coverage, with selective expansion
Within the company’s mix, ACA-focused individual and small-group coverage continues to represent the key growth and earnings driver. Last quarter, premiums before ceded reinsurance reached 4.79 billion US dollars and comprised 98.14% of revenue, effectively driving the 70.40% year-over-year topline lift; membership growth reported mid-year was robust, and investor attention now shifts to the quality and durability of that book through the second half. The company recently announced an expansion into South Carolina and introduced RetireEase, a plan designed to help consumers transition toward Medicare at a predictable cost footprint with access to set prices for preventive visits and common procedures. While the financial contribution from such new offerings may be modest in the near term, they extend the product and geographic footprint and potentially deepen customer relationships, creating a pipeline of membership cohorts that can sustain premium growth and broaden risk pools. This quarter’s narrative will emphasize whether pricing and risk selection continue to balance growth with profitability, especially as additional program integrity checks and eligibility reviews across various cohorts could influence active membership counts and premium revenue recognition. As long as the company preserves disciplined pricing and keeps medical utilization in line with what guidance already anticipates, the most promising driver remains a scalable premium book that can convert membership growth into margin expansion without overstretching on acquisition costs.What will move the stock this quarter: execution versus embedded guidance and membership integrity
Heading into the print, several factors appear most important for share performance. First, the bar: multiple previews point out that the company’s updated outlook already captures better medical utilization trends seen across peers, which can limit the scope for a fresh “beat-and-raise.” In that context, the quality of the quarter—clarity on claims development, reserve movements, and the cadence of reinsurance costs—could matter more than a small outperformance on revenue or EPS. Second, membership integrity and program checks are a live topic; sell-side notes flag additional integrity reviews on large member groups. If cancellations or disenrollments run higher than assumed, reported premium revenue could face modest pressure, potentially offset by improvements in risk scores and utilization if the remaining membership skews higher quality. Third, the signal from capital markets and corporate actions will be monitored: recent insider-selling headlines and a major shareholder’s distribution of shares to limited partners created episodic supply and volatility, and investors will look for stable messaging to steady expectations. Ultimately, the stock’s near-term path will be most sensitive to whether reported medical loss dynamics and membership quality align with the trajectory implied by guidance; if they do, even a modest EPS shortfall could be forgiven, whereas a negative surprise on utilization or churn could weigh on sentiment despite high year-over-year revenue growth.Analyst Opinions
Based on collected previews and rating actions from January 1, 2026 through October 29, 2026, the balance of opinion ahead of the quarter is bearish. Barclays reiterated a Buy and lifted targets in prior months, but more recent, widely circulated previews lean cautious to negative: UBS Securities maintained a neutral stance while explicitly signaling that third-quarter upside is less certain because updated guidance already reflects favorable utilization trends, and Bank of America Securities reiterated an Underperform rating with a 30 US dollars price target, arguing that the longer-range earnings path still hinges on a rebound in exchange enrollment and that projected membership growth in later years may be difficult to achieve. Filtering for directional views on the upcoming quarter’s setup rather than legacy upgrades following the last report, bearish or cautious notes outnumber constructive ones, with at least two well-followed institutions emphasizing downside risks to near-term outperformance versus one bullish reiteration.UBS’s assessment captures the tenor of cautious previews: the firm notes that management’s updated guidance already bakes in better-than-expected utilization seen across the sector, which narrows the runway for another outsized beat on November 5, 2026. The broker raised out-year EPS estimates to reflect structural improvements but stressed that additional program integrity checks on a large member group could weigh on recognized revenue if disenrollment is high. UBS also highlighted that it’s unclear how much of the potential impact from these checks is fully reflected in current guidance, which places a premium on granular disclosures around eligibility and churn in the upcoming report. In practice, that means investors will be parsing not just headline revenue and EPS but also the composition of membership, cadence of premium accruals, and whether management indicates any offsetting levers to preserve margins if active membership tails off in select cohorts.
Bank of America Securities’ Underperform view provides the more overtly negative anchor. It acknowledged the company’s execution on margin improvement to date and suggested that an out-year EPS goal is achievable in principle, but it remained skeptical that ACA exchange enrollment growth will reaccelerate fast enough to match management’s longer-term targets. The house view anticipates a modest decline in enrollment in 2027 and limited growth through 2029, a backdrop that, if directionally right, would make it harder to compound premium revenues at the pace implied by ambitious medium-term milestones. Though this is a multi-year debate, BofA’s caution informs how the market reads the third-quarter print: in the absence of fresh, quantifiable evidence that membership quality and growth are tracking ahead of scenario assumptions, investors could default to the conservative case that sentiment-improving beats may become harder to deliver quarter after quarter.
Goldman Sachs sits in the neutral camp with a Hold, and there have been positive rating actions earlier from other firms, but neither of these alter the near-term skew: a larger share of the current-cycle commentary couches the quarter as a check-in on execution against previously upgraded guidance rather than as a setup for material positive surprise. In practical terms, those bearish-leaning previews imply a market reaction function where the stock may require clear beats on both revenue and profitability, paired with precise commentary on membership integrity, to shift sentiment. Conversely, meeting the modeled 4.72 billion US dollars revenue and -0.22 EPS alongside reiteration of full-year ambitions might be received as adequate but not thesis-changing without added clarity on utilization, risk adjustment, and the durability of the premium base.
The bearish majority view also points investors to a discrete set of disclosures that could change minds. First, a tighter bridge from last quarter’s 22.25% gross margin and 7.41% net margin to the current quarter’s profitability outcomes—showing either stable or expanding spreads despite program checks—would argue that the business is absorbing membership integrity actions without impairing economics. Second, an explicit update quantifying the magnitude, timing, and expected revenue impact of the member eligibility reviews would reduce uncertainty and help the market recalibrate modeled revenue for the fourth quarter and early next year. Third, incremental detail on pricing discipline heading into the new plan year and any early indicators from the expansion markets, including South Carolina, could support confidence that the pipeline of premium growth offsets potential churn in lower-quality segments. If the company delivers on these elements and reiterates or refines guidance credibly, the tone of sell-side commentary could shift, even among houses that remain formally neutral or underperform for now.
In summary, the dominant sell-side setup characterizes the third quarter as a prove-it moment on execution rather than a fresh inflection in fundamentals. The modeled revenue growth of 53.24% year over year and the EPS improvement of 61.41% year over year establish a constructive base case; however, the weight of previews from institutions such as UBS and Bank of America suggest that the hurdle for a materially positive surprise is higher after recent upgrades to guidance. Against that backdrop, the most convincing path to improve sentiment runs through: 1) clean delivery against the modeled 4.72 billion US dollars revenue with resilient margin metrics, 2) a transparent read on membership integrity checks and their financial impact, and 3) reaffirmation of pricing and risk-selection discipline that sustains the premium engine. Until these points are addressed with fresh, quarter-specific evidence, the balance of opinion remains tilted toward caution, and the burden of proof lies with reported numbers and disclosures on November 5, 2026.